Shaping the future of multiple myeloma with artificial intelligence and digital twins: from concept to clinic - Takeaways - MDSpire

Shaping the future of multiple myeloma with artificial intelligence and digital twins: from concept to clinic

  • By

  • Cindy H. Lee

  • Yang Zhang

  • Barbara J. McClure

  • Angelina Yong

  • Hamish S. Scott

  • Chung Hoow Kok

  • March 18, 2026

  • 0 min

Share

  • 1

    Multiple myeloma (MM) is an incurable hematological malignancy characterized by significant clinical and biological heterogeneity.

  • 2

    Artificial intelligence (AI) and digital twin (DT) technologies can enhance risk stratification and therapy selection in MM.

  • 3

    Current risk stratification models for MM include genomic-based definitions of high-risk (HR) disease and functional high-risk (FHR) classifications.

  • 4

    The Mayo Additive Staging System (MASS) identifies subgroups with genomic abnormalities linked to aggressive disease and poor survival.

  • 5

    Future advancements in risk stratification will incorporate additional biological and clinical determinants to improve patient outcomes.

Original Source(s)

Shaping the future of multiple myeloma with artificial intelligence and digital twins: from concept to clinic

  • by Cindy H. Lee, Yang Zhang, Barbara J. McClure, Angelina Yong, Hamish S. Scott, Chung Hoow Kok

  • March 18, 2026

Related Content

Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies

CRISPR Enables In Vivo CAR T Cell Production

In vivo gene editing strategy generates CAR T cells directly inside the body – sidestepping costly manufacturing

  • March 30, 2026

  • 2 min
Romiplostim N01 Enhances Platelet Recovery in Autologous Stem Cell Transplantation with Non-Cryopreserved Peripheral Blood Stem Cells for Plasma Cell Disorders